Cart
sales@molnova.com
Nizubaglustat
CAS No. 1633666-49-5
Nizubaglustat( —— )
Catalog No. M36337 CAS No. 1633666-49-5
Nizubaglustat (AZ3102) is an orally available, selective and brain-permeable dual inhibitor of ceramide glucosyltransferase and non-lysosomal glucosylceramide amidase (NLGase) for the study of neurological diseases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 695 | Get Quote |
|
| 5MG | 1007 | Get Quote |
|
| 10MG | 1349 | Get Quote |
|
| 25MG | 1950 | Get Quote |
|
| 50MG | 2558 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameNizubaglustat
-
NoteResearch use only, not for human use.
-
Brief DescriptionNizubaglustat (AZ3102) is an orally available, selective and brain-permeable dual inhibitor of ceramide glucosyltransferase and non-lysosomal glucosylceramide amidase (NLGase) for the study of neurological diseases.
-
DescriptionNizubaglustat is an inhibitor of Ceramide Glucosyltransferase or Glucosylceramide Synthase (GCS). Nizubaglustat also inhibits GBA2, involving in neuropathological lysosomal storage disorders.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetTransferase
-
RecptorTransferase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1633666-49-5
-
Formula Weight433.51
-
Molecular FormulaC24H32FNO5
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESFC1=C(C=CC(COCCCCCN2[C@@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C2)=C1)C3=CC=CC=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ghisaidoobe AT, et al. Identification and development of biphenyl substituted iminosugars as improved dual glucosylceramide synthase/neutral glucosylceramidase inhibitors. J Med Chem. 2014 Nov 13;57(21):9096-104.?
molnova catalog
related products
-
G43
G43 is a potent and selective glucosyltransferase inhibitor that inhibits GtfB and GtfC with Kd values of 3.7 μM and 46.9 nM, respectively.
-
FGTI-2734
FGTI-2734 can prevent membrane localization of KRAS, hence solving KRAS resistance problem and thwarting mutant KRAS patient-derived pancreatic tumors.?
-
FDW028
FDW028 is a selective and potent fucosyltransferase 8 (FUT8) inhibitor with anti-tumor activity that drives B7-H3 lysosomal degradation via defucosylation and CMA pathways. FUT8 can be used to study metastatic colorectal cancer (mCRC).
